LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) TAGRISSO Shows Clinically Meaningful Survival Improvement In Lung Cancer Study
AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small cell lung cancer, reinforcing its position as a standard-care medication. During the last quarter, the company's stock experienced a 2% rise, aligning closely with broader market trends. Significant developments, such as the approval of Baxdrostat for hypertension and Imfinzi for bladder cancer, alongside robust financial results with increased sales and a higher...